Natco Pharma, operating in the Pharmaceuticals sector and classified as a Smallcap on the BSE, currently has its share price at ₹746.85. The stock has experienced fluctuations today, with a low ...

Tata Equity P/E Fund - (G) 135.15 16,92,000 1.69 Tata Equity P/E Fund-(IDCW-Trigger-Opt B-10%) 135.15 16,92,000 1.69 Tata Equity P/E Fund - (IDCW-Trigger - Opt A - 5% ...

Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is ...

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 14,823.13 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...

Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active ...

Cash Taxes Paid 286.30 177.50 48.20 130.00 ...

The Quarterly Results page of Natco Pharma Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results.

Natco Pharma started in Hyderabad with an investment of ₹3.3 million in 1981 and 20 employees working at a single unit. Today, the company has 8 manufacturing units in Dehradun, Nagarjuna Sagar, ...

Natco Pharma has decided to price Risdiplam, indicated for the treatment of rare genetic disorder Spinal Muscular Atrophy (SMA), at₹15,900. In an update on the legal proceedings on the ...

Drugmaker Natco Pharma on Tuesday said it intends to launch its generic version of spinal muscular atrophy drug Risdiplam only after and subject to successful clarity from the Appellate Bench of ...

A division bench of the Delhi High Court on Wednesday asked Natco Pharma to pause the launch of its drug Risdiplam till April 2 amid a patent dispute with Swiss pharmaceutical giant F Hoffmann-La ...